Earnings ·
Agios reports $55.4M Q3 revenue and $65M net loss, citing strong AQVESME demand
AGIOAgios Pharmaceuticals, Inc.
Agios Pharmaceuticals reported third-quarter 2026 results with net product revenues of $55.4 million, a significant increase from $12.9 million in the prior-year period, driven by the U.S. commercial launch of AQVESME for thalassemia and early access programs in Europe. The company posted a net loss of $65.0 million compared to $103.4 million in Q3 2025, with R&D expenses declining to $73.5 million due to reduced spend on process development and clinical trials. Agios maintains a cash position of $907.0 million as of September 30, 2026, targeting non-GAAP profitability in 2028 while preparing for the potential launch of mitapivat for sickle cell disease following an FDA PDUFA date extension to February 1, 2027.